
    
      To evaluate the improvement of the quality of life of antidepressant monotherapy on Chinese
      patients who meet DSM-5 criteria for the comorbidity of MDD and GAD. To monitor adverse
      events (AEs) and serious adverse events (SAEs) of antidepressant monotherapy
    
  